126 related articles for article (PubMed ID: 15568761)
1. Mechanism-based inactivation of COX-1 by red wine m-hydroquinones: a structure-activity relationship study.
Szewczuk LM; Penning TM
J Nat Prod; 2004 Nov; 67(11):1777-82. PubMed ID: 15568761
[TBL] [Abstract][Full Text] [Related]
2. Potential cancer-chemopreventive activities of wine stilbenoids and flavans extracted from grape (Vitis vinifera) cell cultures.
Waffo-Téguo P; Hawthorne ME; Cuendet M; Mérillon JM; Kinghorn AD; Pezzuto JM; Mehta RG
Nutr Cancer; 2001; 40(2):173-9. PubMed ID: 11962253
[TBL] [Abstract][Full Text] [Related]
3. Resveratrol is a peroxidase-mediated inactivator of COX-1 but not COX-2: a mechanistic approach to the design of COX-1 selective agents.
Szewczuk LM; Forti L; Stivala LA; Penning TM
J Biol Chem; 2004 May; 279(21):22727-37. PubMed ID: 15020596
[TBL] [Abstract][Full Text] [Related]
4. 3-(2-Methoxytetrahydrofuran-2-yl)pyrazoles: a novel class of potent, selective cyclooxygenase-2 (COX-2) inhibitors.
Ranatunge RR; Earl RA; Garvey DS; Janero DR; Letts LG; Martino AM; Murty MG; Richardson SK; Schwalb DJ; Young DV; Zemtseva IS
Bioorg Med Chem Lett; 2004 Dec; 14(24):6049-52. PubMed ID: 15546727
[TBL] [Abstract][Full Text] [Related]
5. Antiplatelet activity of synthetic and natural resveratrol in red wine.
Bertelli AA; Giovannini L; Giannessi D; Migliori M; Bernini W; Fregoni M; Bertelli A
Int J Tissue React; 1995; 17(1):1-3. PubMed ID: 7499059
[TBL] [Abstract][Full Text] [Related]
6. Resveratrol analogues as selective cyclooxygenase-2 inhibitors: synthesis and structure-activity relationship.
Murias M; Handler N; Erker T; Pleban K; Ecker G; Saiko P; Szekeres T; Jäger W
Bioorg Med Chem; 2004 Nov; 12(21):5571-8. PubMed ID: 15465334
[TBL] [Abstract][Full Text] [Related]
7. Low concentrations of resveratrol potentiate the antiplatelet effect of prostaglandins.
Wu CC; Wu CI; Wang WY; Wu YC
Planta Med; 2007 May; 73(5):439-43. PubMed ID: 17566146
[TBL] [Abstract][Full Text] [Related]
8. Grapes, wines, resveratrol, and heart health.
Bertelli AA; Das DK
J Cardiovasc Pharmacol; 2009 Dec; 54(6):468-76. PubMed ID: 19770673
[TBL] [Abstract][Full Text] [Related]
9. Cardioprotection of red wine: role of polyphenolic antioxidants.
Das DK; Sato M; Ray PS; Maulik G; Engelman RM; Bertelli AA; Bertelli A
Drugs Exp Clin Res; 1999; 25(2-3):115-20. PubMed ID: 10370873
[TBL] [Abstract][Full Text] [Related]
10. Neuroprotective abilities of resveratrol and other red wine constituents against nitric oxide-related toxicity in cultured hippocampal neurons.
Bastianetto S; Zheng WH; Quirion R
Br J Pharmacol; 2000 Oct; 131(4):711-20. PubMed ID: 11030720
[TBL] [Abstract][Full Text] [Related]
11. Viniferin formation by COX-1: evidence for radical intermediates during co-oxidation of resveratrol.
Szewczuk LM; Lee SH; Blair IA; Penning TM
J Nat Prod; 2005 Jan; 68(1):36-42. PubMed ID: 15679314
[TBL] [Abstract][Full Text] [Related]
12. Flavonoids and stilbenoids with COX-1 and COX-2 inhibitory activity from Dracaena loureiri.
Likhitwitayawuid K; Sawasdee K; Kirtikara K
Planta Med; 2002 Sep; 68(9):841-3. PubMed ID: 12357401
[TBL] [Abstract][Full Text] [Related]
13. Does white wine qualify for French paradox? Comparison of the cardioprotective effects of red and white wines and their constituents: resveratrol, tyrosol, and hydroxytyrosol.
Dudley JI; Lekli I; Mukherjee S; Das M; Bertelli AA; Das DK
J Agric Food Chem; 2008 Oct; 56(20):9362-73. PubMed ID: 18821770
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of cyclooxygenase (COX) enzymes by compounds from Daucus carota L. Seeds.
Momin RA; De Witt DL; Nair MG
Phytother Res; 2003 Sep; 17(8):976-9. PubMed ID: 13680840
[TBL] [Abstract][Full Text] [Related]
15. Cyclooxygenase (COX) inhibitors: a comparative QSAR study.
Garg R; Kurup A; Mekapati SB; Hansch C
Chem Rev; 2003 Mar; 103(3):703-32. PubMed ID: 12630850
[No Abstract] [Full Text] [Related]
16. The classification of cyclooxygenase inhibitors.
Lipsky LP; Abramson SB; Crofford L; Dubois RN; Simon LS; van de Putte LB
J Rheumatol; 1998 Dec; 25(12):2298-303. PubMed ID: 9858421
[TBL] [Abstract][Full Text] [Related]
17. [New NSAIDS: COX-1, COX-2, what about them?].
Peretz A
Rev Med Brux; 1998 Sep; 19(4):A399-402. PubMed ID: 9805982
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of COX isoforms by nutraceuticals.
Seaver B; Smith JR
J Herb Pharmacother; 2004; 4(2):11-8. PubMed ID: 15364641
[TBL] [Abstract][Full Text] [Related]
19. Involvement of cyclooxygenase-derived prostaglandin E2 and nitric oxide in the protection of rat pancreas afforded by low dose of lipopolysaccharide.
Jaworek J; Bonior J; Tomaszewska R; Jachimczak B; Kot M; Bielański W; Pawlik WW; Sendur R; Stachura J; Konturek PC; Konturek SJ
J Physiol Pharmacol; 2001 Mar; 52(1):107-26. PubMed ID: 11321505
[TBL] [Abstract][Full Text] [Related]
20. Pleiotropic effects of resveratrol.
Granados-Soto V
Drug News Perspect; 2003 Jun; 16(5):299-307. PubMed ID: 12942161
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
